Literature DB >> 18087679

Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction.

R Preston Mason1, Ruslan Kubant, Gehan Heeba, Robert F Jacob, Charles A Day, Yehudi S Medlin, Philipp Funovics, Tadeusz Malinski.   

Abstract

PURPOSE: Statins and certain calcium channel blockers may improve nitric oxide (NO) release and endothelial function through various mechanisms, but their combined effects are not well understood.
METHODS: The separate versus combined effects of amlodipine (AML) and atorvastatin (AT) on NO and peroxynitrite (ONOO-) were measured in human umbilical vein endothelial cells (HUVEC) in the presence and absence of low-density lipoprotein (LDL) using electrochemical nanosensors.
RESULTS: The combination of AML (5 micromol/l) and AT (3-6 micromol/l) directly stimulated NO release that was about twofold greater than the sum of their separate effects (p < 0.05). This synergistic activity is attributed to enhanced endothelial NO synthase (eNOS) function and decreased cytotoxic ONOO-. LDL (100 mg/dl) caused a dysfunction of HUVEC manifested by a 60% reduction in NO and an almost twofold increase in ONOO-. Treatment with AML/AT partially reversed the effects of LDL on endothelial function, including a 90% increase in NO and 50% reduction in ONOO-. Small-angle X-ray diffraction analysis indicates that AML and AT are lipophilic and share an overlapping molecular location in the cell membrane that could facilitate electron transfer for antioxidant mechanisms.
CONCLUSION: These findings indicate a synergistic effect of AML and AT on an increase in NO concentration, reduction of nitroxidative stress. Also, AML/AT partially restored the NO level of LDL-induced dysfunctional endothelium. Their combined effects may be enhanced by antioxidant properties related to their intermolecular actions in the cell membrane and an increase in the expression and coupling of endothelial nitric oxide synthase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18087679     DOI: 10.1007/s11095-007-9491-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  57 in total

Review 1.  Endothelium-dependent effects of statins.

Authors:  Sebastian Wolfrum; Kristin S Jensen; James K Liao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-27       Impact factor: 8.311

2.  Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.

Authors:  Peter Sever; Björn Dahlöf; Neil Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre Kjeldsen; Arni Kristinsson; Gordon McInnes; Jesper Mehlsen; Markku Nieminem; Eoin O'Brien; Jan Ostergren
Journal:  Eur Heart J       Date:  2006-12-04       Impact factor: 29.983

3.  Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.

Authors:  O Feron; C Dessy; J P Desager; J L Balligand
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

4.  Partitioning and location of Bay K 8644, 1,4-dihydropyridine calcium channel agonist, in model and biological membranes.

Authors:  R P Mason; G E Gonye; D W Chester; L G Herbette
Journal:  Biophys J       Date:  1989-04       Impact factor: 4.033

5.  Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent.

Authors:  X Zhang; T H Hintze
Journal:  Circulation       Date:  1998-02-17       Impact factor: 29.690

6.  Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells.

Authors:  F Vidal; C Colomé; J Martínez-González; L Badimon
Journal:  Eur J Biochem       Date:  1998-03-15

7.  Role of endothelial nitric oxide in shear stress-induced vasodilation of human microvasculature: diminished activity in hypertensive and hypercholesterolemic patients.

Authors:  O A Paniagua; M B Bryant; J A Panza
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

8.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

9.  Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis.

Authors:  L Kalinowski; I T Dobrucki; T Malinski
Journal:  J Physiol Pharmacol       Date:  2002-12       Impact factor: 3.011

10.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.

Authors:  T J Anderson; I T Meredith; A C Yeung; B Frei; A P Selwyn; P Ganz
Journal:  N Engl J Med       Date:  1995-02-23       Impact factor: 91.245

View more
  12 in total

Review 1.  Role of lipotoxicity in endothelial dysfunction.

Authors:  Jeong-a Kim; Monica Montagnani; Sruti Chandrasekran; Michael J Quon
Journal:  Heart Fail Clin       Date:  2012-08-10       Impact factor: 3.179

Review 2.  Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.

Authors:  Kirtiman Srivastava; Philip M W Bath; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2011-12-25       Impact factor: 5.046

3.  Angiotensin II decreases nitric oxide synthase 3 expression via nitric oxide and superoxide in the thick ascending limb.

Authors:  Vanesa D Ramseyer; Jeffrey L Garvin
Journal:  Hypertension       Date:  2008-12-15       Impact factor: 10.190

4.  Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?

Authors:  John E Deanfield; Phillipe Sellier; Erik Thaulow; Jan Bultas; Carla Yunis; Harry Shi; Jan Buch; Bruce Beckerman
Journal:  Eur Heart J       Date:  2010-05-21       Impact factor: 29.983

5.  Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes.

Authors:  R Preston Mason; Robert F Jacob; J Jose Corbalan; Roman Kaliszan; Tadeusz Malinski
Journal:  Am J Hypertens       Date:  2013-10-29       Impact factor: 2.689

Review 6.  Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.

Authors:  Monique P Curran
Journal:  Drugs       Date:  2010       Impact factor: 9.546

7.  Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling.

Authors:  Charalambos Antoniades; Constantinos Bakogiannis; Paul Leeson; Tomasz J Guzik; Mei-Hua Zhang; Dimitris Tousoulis; Alexios S Antonopoulos; Michael Demosthenous; Kyriakoula Marinou; Ashley Hale; Andreas Paschalis; Costas Psarros; Costas Triantafyllou; Jennifer Bendall; Barbara Casadei; Christodoulos Stefanadis; Keith M Channon
Journal:  Circulation       Date:  2011-07-05       Impact factor: 29.690

8.  Combining antihypertensive and antihyperlipidemic agents - optimizing cardiovascular risk factor management.

Authors:  José Zamorano; Jonathan Edwards
Journal:  Integr Blood Press Control       Date:  2011-11-15

Review 9.  Pleiotropic effects of calcium channel blockers.

Authors:  R Preston Mason
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

10.  Amlodipine Ameliorates Ischemia-Induced Neovascularization in Diabetic Rats through Endothelial Progenitor Cell Mobilization.

Authors:  Jiayin Sun; Jun Xie; Lina Kang; Albert Ferro; Li Dong; Biao Xu
Journal:  Biomed Res Int       Date:  2016-05-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.